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In Brief
ADARmutations cause Aicardi-Goutie`res
syndrome, a severe human autoimmune
disease, but how ADAR1 regulates
autoimmunity remains unknown. Stetson
and colleagues reveal two functions for
ADAR1: prevention of MDA5- and MAVS-
dependent autoimmunity and control of
multi-organ development.
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Mutations in ADAR, which encodes the ADAR1 RNA-
editing enzyme, cause Aicardi-Goutie`res syndrome
(AGS), a severe autoimmune disease associated
with an aberrant type I interferon response. How
ADAR1 prevents autoimmunity remains incompletely
defined. Here, we demonstrate that ADAR1 is a
specific and essential negative regulator of the
MDA5-MAVS RNA sensing pathway. Moreover, we
uncovered a MDA5-MAVS-independent function for
ADAR1 in the development of multiple organs. We
showed that the p150 isoform of ADAR1 uniquely
regulated the MDA5 pathway, whereas both the
p150 and p110 isoforms contributed to development.
Abrupt deletion of ADAR1 in adult mice revealed that
both of these functionswere required throughout life.
Our findings delineate genetically separable roles for
both ADAR1 isoforms in vivo, with implications for
the human diseases caused by ADAR mutations.
INTRODUCTION
Intracellular detection of foreign nucleic acids initiates the pro-
duction of type I interferons (IFNs) and is essential for host
defense against virus infection (Goubau et al., 2013). Character-
ization of the RIG-I-like receptor-MAVS RNA-sensing pathway
and the cGAS-STING DNA-sensing pathway has illuminated
the earliest events of virus detection in molecular detail (Wu
and Chen, 2014). Given the millions of molecules of RNA and
the billions of base pairs of genomic DNA present in all nucleated
cells, negative regulation of these pathways has emerged as a
key mechanism to prevent autoreactivity. Much of our under-
standing of this regulation comes from the genetic dissection
of a severe human autoimmune disease called Aicardi-Goutie`res
syndrome (AGS), first described more than 30 years ago as a
monogenic disorder associated with the aberrant production of
type I IFNs (Aicardi and Goutie`res, 1984; Lebon et al., 1988).
Crow and colleagues have identified seven human genes that
are mutated in AGS, providing a framework for studying theImechanisms that limit activation of intracellular nucleic acid sen-
sors: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1,
ADAR, and IFIH1 (MDA5) (Crow et al., 2015; Crow and Manel,
2015).
Among the best characterized of the AGS enzymes is Trex1, a
cytosolic DNA exonuclease. Trex1-deficient mice develop lethal
autoimmune disease that is entirely dependent on cGAS, STING,
the IRF3 transcription factor, the type I IFN receptor, and lym-
phocytes, thus defining Trex1 as a specific and essential nega-
tive regulator of the intracellular DNA-sensing pathway (Ablasser
et al., 2014; Gall et al., 2012; Gao et al., 2015; Gray et al., 2015;
Stetson et al., 2008). Similarly, SAMHD1 is a dNTP phosphohy-
drolase that prevents cDNA synthesis by retroviral reverse tran-
scriptase enzymes, strongly suggesting that the cGAS-STING
pathway also drives autoimmunity in AGS caused by SAMHD1
mutations (Goldstone et al., 2011; Hrecka et al., 2011; Laguette
et al., 2011; Rehwinkel et al., 2013). Interestingly, identification of
the innate immune pathway regulated by RNase H2 is compli-
cated by the early embryonic lethality of RNase H2-deficient
mice, caused by accumulation of ribonucleotides in genomic
DNA and massive genome instability (Hiller et al., 2012; Reijns
et al., 2012).
The identification of AGS mutations in ADAR that encodes the
ADAR1 enzyme revealed a disease mechanism that does not fit
into the cGAS-STING pathway (Rice et al., 2012). ADAR in mam-
mals encodes two open reading frames that give rise to two
protein isoforms: a p110 isoform that is constitutively and ubiq-
uitously expressed and a larger p150 isoform that is IFN induc-
ible and contains two complete zDNA-binding domains that
are not found in p110 (Bass, 2002; Schwartz et al., 1999).
ADAR1 is a deaminase that converts adenosine to inosine
(A to I) within double-stranded regions of RNA (Bass, 2002). In
coding regions, inosine is decoded as guanosine (G), leading
to amino acid changes or stop codon read-through at edited
sites. In introns of mRNAs, editing can create or destroy splice
acceptor sites. In double-stranded regions of RNA, the I-U
base pair is unstable compared to the parental A-U base pair,
leading to changes in secondary structure of RNA that can result
in degradation (Wang et al., 2013). In mammals, ADAR1 edits
coding RNAs (Hartner et al., 2004), microRNAs (Yang et al.,
2006), and the RNA transcripts of the prolific SINE retroelements
(Osenberg et al., 2010). Interestingly, ADAR1 deficiency in
mice results in embryonic lethality, accompanied by massivemmunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc. 933
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Figure 1. Rescue of Adar–/– Mice to Birth by Ifih1/Mda5 and MAVS
Deficiency
Live births from Adar+/ (A), Adar+/Tmem173/ (B), Adar+/Mavs/ (C),
Adar+/Ifih1/ (D), and Adar+/Ddx58+/ (E) intercross. Percent rescue
p > 0.05 by chi square goodness-of-fit for Adar+/Mavs/ intercross and
Adar+/Ifih1/ intercross.overproduction of type I IFNs and hematopoietic failure (Hartner
et al., 2004, 2009; Wang et al., 2000). A number of mechanisms
have been proposed to explain the dramatic phenotype of
Adar/ mice, including roles for ADAR1 in modulation of
microRNA biogenesis (Ota et al., 2013), control of the length
of mRNA 30 untranslated regions (UTRs) (Bahn et al., 2015),
physical sequestration of RNAs from RIG-I (Yang et al., 2014),
and the direct suppression of RIG-I and MDA5 activity by
RNAs that contain inosine (Vitali and Scadden, 2010). In addition,
a recent study identified live births of Adar/Mavs/ mice
(Mannion et al., 2014). However, the precise innate immune
pathways regulated by ADAR1 and the contributions of these
pathways to the phenotypes of Adar/ mice remain undefined.
In this study, we define ADAR1 as a specific negative regulator
of the MDA5-MAVS pathway. Moreover, we reveal an essential
role for ADAR1 in multi-organ development and homeostasis
that is independent of the MDA5-MAVS pathway. We show
that the two isoforms of ADAR1 contribute independently to
each of these functions.
RESULTS
ADAR1 Is a Specific Negative Regulator of the
MDA5-MAVS Pathway
To define the innate immune receptor(s) and signaling pathways
responsible for the embryonic lethality of Adar/ mice,
we analyzed more than 700 live births of Adar+/ intercrosses,
alone and on four additional genetic backgrounds: Tmem173
(Sting)/, Mavs/, Ifih1 (Mda5)/, and Ddx58 (Rigi)+/. Con-934 Immunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc.sistent with previous reports defining fully penetrant embryonic
lethality of Adar/ mice (Hartner et al., 2004; Wang et al.,
2000), we found no live births of Adar/ mice (Figure 1A).
Similarly, no Adar/Tmem173/ mice were born, and the fre-
quencies of live Adar+/+Tmem173/ and Adar+/Tmem173/
mice were indistinguishable from mice born from the Adar+/
intercross, formally demonstrating that the STING pathway plays
no role in the phenotypes associated with ADAR1 deficiency
(Figure 1B). In contrast, and consistent with a recent report (Man-
nion et al., 2014),Adar/Mavs/micewere born at frequencies
that were statistically indistinguishable from expected Mende-
lian ratios (Figure 1C). Thus, the MAVS pathway, and not the
STING pathway, drives the embryonic lethality of Adar/ mice.
We next evaluated intercrosses of Adar+/ mice with mice
lacking the two principal RNA sensors upstream of MAVS:
MDA5 (Ifih1) and RIG-I (Ddx58) (Kato et al., 2006). Remarkably,
Adar/Ifih1/ mice were born at expected Mendelian fre-
quencies (Figure 1D). The Adar-Ddx58 cross was complicated
by the embryonic lethality of most Ddx58/ mice (Kato et al.,
2005), which occurs for reasons that remain poorly defined.
Therefore, we bred Adar+/mice to Ddx58+/mice and analyzed
more than 300 live births. We recovered only two Ddx58/ sin-
gle mutant mice and no Adar/Ddx58/ mice (Figure 1E).
We performed timed matings of Adar+/ mice on the four
backgrounds described above, harvested embryos at day 11.5
of development (E11.5, before the onset of lethality in Adar/
mice), and assessed the innate immune response via quantita-
tive RT-PCR analysis of six interferon-stimulated genes (ISGs).
We found that MAVS deficiency completely reversed the
elevated ISG signature of Adar/ embryos, but STING defi-
ciency had no effect (Figure 2A). Moreover, and identical to
Adar/Mavs/ embryos, we found that Adar/Ifih1/ em-
bryos also lacked the increased ISG expression seen in Adar/
embryos. Importantly, the single Adar/Ddx58/ embryo that
we recovered had elevated ISG expression that was identical
to control Adar/Ddx58+/+ embryos (Figure 2B). Taken
together, these data define MDA5-MAVS, and not RIG-I-
MAVS, as the specific innate immune pathway responsible for
both the dysregulated ISG expression and the embryonic
lethality of Adar/ mice.
To extend our findings to human cells, we used a lenti-CRISPR
approach to disrupt the endogenous ADAR gene in HEK293T
cells. We designed a guide RNA to target an exon shared by
both isoforms of ADAR1, transduced and selected targeted
cells, and then derived a clonal line of ADAR-null cells with
frameshift mutations in all three alleles of ADAR (Figure 3A;
HEK293T cells are triploid for chromosome 3). We confirmed
by immunoblot that these ADAR-null cells lacked expression of
both isoforms of ADAR1 protein (Figure 3B). We then introduced
expression vectors for either RIG-I or MDA5 into these cells or
control cells and measured the IFN response via an interferon-
stimulated response element (ISRE)-luciferase reporter. We
found that RIG-I responded identically in control and ADAR-
null cells at each concentration of transfected expression vector
(Figure 3C). Remarkably, the MDA5-activated IFN response was
enhanced inADAR-null HEK293T cells compared to control cells
at all concentrations of plasmid (Figure 3C). These findings,
together with our analysis ofAdar/mice and embryos, strongly
suggest that ADAR1 deficiency results in the accumulation of
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Figure 2. MDA5 and MAVS Deficiency Reverse the IFN Signature in
Adar–/– Embryos
Quantitative RT-PCR on a panel of six ISGs from whole E11.5 embryos.
(A) Adar+/+ (white, n = 3), Adar/ (gray, n = 3), Adar/Sting/ (blue, n = 4),
Adar/Mavs/ (red, n = 5). Interferon signature assessed byWilcoxon signed
rank test compared to Adar+/+: Adar/ p = 0.03, Adar/Sting/ p = 0.03,
Adar/Mavs/ p = 0.31.
(B) Adar+/+Ifih1/ (white, n = 3), Adar/Ifih1/ (red, n = 3), Adar-+/+Ddx58+/+
(white stripes, n = 3), Adar/Ddx58+/+ (gray stripes, n = 2), Adar+/+Ddx58/
(light blue stripes, n = 2), Adar/Ddx58/ (blue stripes, n = 1). Interferon
signature assessed byWilcoxon signed rank test compare to Adar+/+ controls,
Adar/Ifih1/ p = 0.56,Adar/Ddx58+/+ p = 0.03,Adar+/+Ddx58/ p = 0.69,
Adar/Ddx58/ p = 0.03.endogenous, immunostimulatory RNAs that are specifically de-
tected by MDA5 and not by RIG-I.
MAVS-Dependent and MAVS-Independent Gene
Expression Changes in Adar–/– Embryos
To assess global changes in gene expression caused by ADAR1
deficiency beyond the specific ISGs analyzed in Figure 2, we
performed RNA-seq analysis of gene expression in whole
E11.5 embryos, comparing Adar/ to Adar+/+ embryos, as
well as Adar/Mavs/ to Adar+/+Mavs/ embryos (Figure 4
and Tables S1 and S2). In both cases, the great majority of dys-
regulated genes exhibited increased expression in the Adar/Iembryos compared to respective controls, suggesting that
ADAR1 is primarily a negative regulator of gene expression (Fig-
ures 4A and 4B). We found more than 900 genes with signifi-
cantly different expression levels in Adar/ versus Adar+/+
embryos, 180 of which were ISGs (Figure 4A). As expected,
the increased expression of nearly all of these ISGs was restored
to normal levels in the Adar/Mavs/ embryos (Figures 4A
and 4B, red dots). However, and unexpectedly, we identified
more than 200 genes with similarly dysregulated expression in
both Adar/ and Adar/Mavs/ embryos compared to their
respective controls (Figures 4A–4C, blue dots). Bioinformatics
analysis of these genes revealed highly enriched biological pro-
cesses and transcription factor networks controlled by ADAR1 in
a MAVS-independent fashion. These included genes involved in
lipid metabolism and transport, associated with upregulation of
PPAR-g transcriptional targets in Adar/ embryos (Figures 4D
and 4E). Moreover, we identified targets of the TCF1, TCF14,
TCF3, and HOXA13 transcription factors that control cell fate
specification during development (Figures 4D and 4E). Impor-
tantly, we found no evidence for residual inflammatory gene
expression in Adar/Mavs/ embryos (Figures 4D and 4E),
suggesting that the entire dysregulated innate immune response
caused by ADAR1 deficiency depends onMAVS signaling. Thus,
ADAR1 controls expression of two classes of genes: the first
class is innate immune response genes driven by MAVS
signaling, whereas the second class is MAVS independent and
implicated in development and metabolism.
MDA5-MAVS-Independent Control of Multi-organ
Development by ADAR1
Consistent with the identification of a substantial set of MAVS-in-
dependent genes regulated by ADAR1 (Figure 4), we observed a
fully penetrant postnatal mortality in both Adar/Mavs/ mice
and Adar/Ifih1/mice, with the majority of neonates dying by
2 days of age (Figures 5A and 5B). We analyzed the phenotypes
of the small number of Adar/Mavs/ mice that survived past
1 week of age, comparing them to Adar+/+Mavs/ littermates.
The double knockout mice were severely runted compared to
their Mavs/ littermates, but they appeared to be feeding, as
evidenced by the presence of milk in their stomachs (data not
shown). However, the Adar/Mavs/ mice were largely unre-
sponsive and immobile, with a ‘‘trembling’’ phenotype (Movie
S1). We performed a thorough histological analysis of tissues
and organs in three mice of each genotype, revealing a
number of novel, MAVS-independent developmental pheno-
types caused by ADAR1 deficiency. First, the kidneys of
Adar/Mavs/ mice had a profound change in architecture,
with multiple discrete lobes of the outer medulla and marked
disorganization of the tubules in the corticomedullary junction
(Figure 5C). This contrasts with the single-lobed outer medulla
of normal rodent kidneys, revealing an unexpected role for
ADAR1 in regulation of kidney patterning during development.
Second, we observed a dramatic dysregulation of gastrointes-
tinal homeostasis in Adar/Mavs/ mice (Figure 5C). This
phenotype was apparent throughout the intestine, although
most pronounced in the small intestine. Intestinal lesions
included moderate superficial enterocyte vacuolation, mild
to moderate villar fusion, and extensive apoptosis of enterocytes
that was especially pronounced in the crypts, with mildmmunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc. 935
AB C
Figure 3. ADAR1 Specifically Regulates the
MDA5 Pathway in Human Cells
(A) Generation of ADAR-null HEK293T cells by
lentiCRISPR targeting. The CRISPR target site in
exon 4 of ADAR is indicated in blue, and the pro-
tospacer adjacent motif (PAM) is shown in green.
The Cas9 cleavage site is indicated with an arrow.
Deletions in the three ADAR alleles, each of which
results in a frameshift, are shown by the red
dashes.
(B) Immunoblot of ADAR1 protein using lysates
from control HEK293T cells and an ADAR-
lentiCRISPR-targeted clone of HEK293T cells.
(C) The indicated HEK293T cells were transfected
with 25 ng ISRE-luciferase reporter plasmid, with
or without the indicated amounts of plasmids en-
coding RIG-I or MDA5. Cells were analyzed for
relative luciferase units 24 hr after transfection.
Mean ± SD; ***p < 0.0001 in two-way ANOVA test
with Tukey’s multiple comparison. Data are
representative of four independent experiments.proliferation and mild mixed inflammation (enteritis; Figure 5C).
Third, we found a near complete lack of organized lymphoid fol-
licles in both lymph nodes and spleens of Adar/Mavs/mice,
on both histology (Figure 5C) and immunofluorescence micro-
scopy performed to localize T cells and B cells (Figure 5D). In
the spleens of Adar/Mavs/ mice, there was extramedullary
hematopoiesis of both myeloid and erythroid lineages (Fig-
ure 5C). Fourth, flow cytometry analysis of splenocytes revealed
a dramatic reduction in the frequency of mature B cells but rela-
tively normal numbers of T cells, aswell as increased frequencies
of CD11c+ dendritic cells (Figure 5E). These phenotypes of
Adar/Mavs/ mice reveal an essential role for ADAR1 in the
development and homeostasis of multiple organs, independent
of its role as a negative regulator of the MDA5-MAVS-mediated
antiviral response. Importantly, we demonstrate that the failure
of hematopoiesis in Adar/ mice is an indirect consequence
of the aberrant, MDA5-MAVS-dependent antiviral response,
revealing instead a selective, MDA5-MAVS-independent role
for ADAR1 in development of B cells.
Independent Contributions of ADAR1 Isoforms to
Regulation of MDA5-MAVS and Development
We evaluated the relative in vivo contributions of the p150 and
p110 isoforms of ADAR1 to regulation of MDA5-MAVS-depen-
dent autoimmunity versus MDA5-MAVS-independent organ
development. To do this, we studied Adar p150/ mice, which
were generated by targeted disruption of the unique promoter
and first exon that encodes the amino terminus of the p150 iso-
form (Ward et al., 2011).Adar p150/mice are embryonic lethal,
similar to Adar/ mice that lack both the p150 and p110 iso-
forms of ADAR1 (Ward et al., 2011). Given that the embryonic
lethality of Adar/ mice is entirely MDA5 and MAVS dependent
(Figure 1), we hypothesized that the ADAR1 p150 isoform might
specifically regulate the MDA5-MAVS pathway. We performed
immunoblot analysis of Adar p150+/ and Adar p150/MEF ex-
tracts and confirmed the absence of p150 protein, but normal936 Immunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc.levels of the p110 isoform, in these cells (Figure 6A). Next, we in-
tercrossed Adar p150+/Mavs/ mice and observed complete
rescue of the Adar p150/Mavs/mice to birth, demonstrating
that the p150 isoform of ADAR1 is the unique and essential nega-
tive regulator of theMAVS pathway (Figure 6B). Remarkably, and
unlike the Adar/Mavs/mice that died shortly after birth (Fig-
ure 5A), most of the Adar p150/Mavs/ mice survived to
weaning (Figure 6C). Moreover, these mice were active and mo-
bile, ate solid food, and did not tremble, although they were
smaller than their control littermates (Movie S1). We performed
a histological analysis of Adar p150/Mavs/mice, comparing
them to Adar/Mavs/ mice (Figure 5) and to controls. We
found that the kidney abnormalities that were present in the
Adar/Mavs/ mice were largely absent in Adar p150/
Mavs/ mice, demonstrating that p110 is a specific regulator
of kidney development (Figure 6D). However, the dysregulated
intestinal homeostasis was similar between Adar p150/
Mavs/ mice compared to the Adar/Mavs/ mice (Fig-
ure 6D). Moreover, the lymph nodes and spleens of Adar
p150/Mavs/mice were still devoid of lymphoid follicles (Fig-
ure 6D). Consistent with this, we observed reduced numbers of
peripheral B cells and increased numbers of CD11c+ myeloid
cells in Adar p150/Mavs/ mice (Figure 6E), identical to
Adar/Mavs/ mice (Figure 5E). Thus, expression of the
p110 isoform of ADAR1 in Adar p150/Mavs/ mice is suffi-
cient to restore kidney development, but not intestinal homeo-
stasis or B cell development.
We next examined editing of the mRNA encoding the 5-HT2C
serotonin receptor that mediates numerous actions of serotonin
in the central nervous system, including feeding and sleep
behavior, as well as inhibition of neuronal excitability (Frank
et al., 2002; Tecott et al., 1995). A prior study identified
ADAR1-dependent editing at two specific adenosines within
the 5-HT2C open reading frame in cultured embryonic neurons,
termed the ‘‘A’’ and ‘‘B’’ sites (Hartner et al., 2004). We therefore
measured editing of these sites in cDNAs prepared from brains
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Figure 4. MAVS-Dependent and MAVS-Independent Gene Expression in Adar–/– Embryos
RNA-seq was performed on rRNA-depleted RNA from whole E11.5 embryos of the indicated genotypes.
(A) Comparison of gene expression betweenAdar/ (n = 3) andAdar+/+ (n = 3) embryos. Data are plotted as log2 fold change in gene expression on the y axis, with
normalized log2 counts per million (CPM) on the x axis. Grey dots denote genes with insignificant differences in expression. Blue dots denote non-ISGs with
differential expression (p% 0.01). Red dots indicate ISGs with differential expression (p% 0.01).
(B) Comparison of gene expression between Adar/Mavs/ (n = 3) and Mavs/ (n = 3) embryos, using the same criteria as in (A).
(C) Genes with differential expression (p % 0.01) in either pairwise comparison were plotted, with Adar/ versus Adar+/+ on the y axis, and Adar/Mavs/
versus Mavs/ on the x axis. Blue and red genes are the same as (A) and (B).
(D) Biological pathways enriched among the genes with dysregulated expression in both Adar/ embryos and Adar/Mavs/embryos identified in (C).
(E) Transcription factor binding sites enriched among the MAVS-independent differentially expressed genes from (C).
For (D) and (E), fold enrichment relative to the representation of these pathways in the genome is shown on the left y axis and the blue bars. Significance of
enrichment is indicated by hyper geometric p value on the right y axis and the black symbols/line. Analysis was performed with FunRich software.of 20-day-old Adar/Mavs/ and Adar p150/Mavs/
mice. Consistent with the prior study, we found that both the
A and B sites of 5-HT2C mRNAs were extensively edited in con-
trol Mavs/ mice and that this editing was absent in Adar/
Mavs/ mice (Figure 6F). Interestingly, the Adar p150/
Mavs/ mice had normal levels of editing at these sites,
demonstrating that ADAR1 p110 is both necessary and sufficient
for editing of these sites in vivo (Figure 6F). This finding reveals a
specific editing event mediated by p110 and not by p150. These,
as well as other potential p110-specific editing events thatIremain to be identified, might contribute to the phenotypic
differences between Adar/Mavs/ mice and Adar p150/
Mavs/ mice. Together, these data demonstrate independent
roles for ADAR1 isoforms: the p150 isoform regulates the MDA5-
MAVS pathway, and both isoforms contribute to development.
ADAR1 Controls Both Innate Immunity and Homeostasis
in Adult Mice
Our findings demonstrating roles for ADAR1 in controlling both
the MDA5-MAVS pathway and multi-organ development led usmmunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc. 937
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Figure 5. Postnatal Mortality and Severe Developmental Defects in Adar–/–Mavs–/– Mice
(A and B) Postnatal survival curves for Adar/Mavs/ (A) and Adar/Ifih1/ (B) mice.
(C) Adar/Mavs/ mice have developmental defects of the kidney (top row; papillae marked with black asterisks), small intestine (second row), lymph node
(third row; follicles marked with white asterisks), and spleen (fourth row; lymphoid regions enclosed by dashed circle). Images are hematoxylin and eosin with
magnification indicated.
(D) Immunofluorescence microscopy of splenic sections with anti-B220 (green), anti-CD8 and anti-CD4 (red), and DAPI (blue).
(E) Analysis of splenocytes by flow cytometry shows severe B cell deficiency in Adar/Mavs/ mice.
Mice in (C) were 20 days old. Mice in (D) were 15 days old. Mice in (E) were 13 days old.to test whether these functions are similarly required in adult
mice. We crossed mice with a floxed Adar allele (Adarfl/fl)
(Hartner et al., 2009) to mice expressing a tamoxifen-inducible
Ert2-Cre transgene under the control of the broadly expressed
UBC promoter (Ruzankina et al., 2007) on both Mavs+/+ and
Mavs/ backgrounds. We treated these mice daily for 3 days
by intraperitoneal injection of tamoxifen, which resulted in wide-
spread deletion of the floxed Adar alleles in Ert2-Cre-expressing
mice as measured by genotyping of ear tissue (Figure 7A). We938 Immunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc.found that the tamoxifen injections resulted in a drop in body
temperature in all treated mice, regardless of Cre expression
or Adar genotype (Figure 7B). 1 day after the third tamoxifen
treatment, and only 4 days after the initial treatment, we found
that the Adarfl/flMavs+/+Ert2-Cre-expressing mice had an exac-
erbated reduction in body temperature (Figure 7B), were
hunched and unresponsive, and required immediate euthanasia.
Wemeasured the abundance of 32 serum cytokines and chemo-
kines in thesemice and controls and found dramatically elevated
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Figure 6. Independent Roles for ADAR1 Isoforms in Regulation of MDA5-MAVS and Development
(A) Immunoblot of ADAR1 protein expression in p150+/ or p150/ MEFs.
(B) Live births for mice from the p150+/Mavs/ intercross.
(C) Postnatal survival curves for mice from the p150+/Mavs/ intercross.
(D) Hematoxylin and eosin-stained tissue sections of the indicated organs of p150/Mavs/ mice and controls are shown, with magnification indicated.
(E) Analysis of splenocytes by flow cytometry shows severe B cell deficiency and an increase in CD11c+myeloid cells in p150/Mavs/mice. Two-sample t test
for p values; p150+/+Mavs/ n = 3, p150/Mavs/ n = 3; ***p < 0.002, **p = 0.004.
(F) Representative chromatograms of 2-HT2C receptor transcript editing in brains of 15- to 21-day-old mice of the indicated genotypes.
Mice in (D) were 15 days old. Mice in (E) and (F) were 21 days old.levels of many of them, including TNFa, CXCL10, and IL-10, thus
revealing a profound systemic inflammatory response instigated
by abrupt Adar deletion on aMavs+/+ background (Figure 7C). In
contrast, the Adarfl/flMavs/ Ert2-Cre-expressing mice recov-
ered body temperature after cessation of tamoxifen treatments
and appeared healthy for 5 more days (Figure 7B). At day 8 after
treatment, we noted that these mice were abnormal compared
to controls, so we prepared these mice for serum cytokine anal-
ysis and histological evaluation. We found that the systemic
cytokine response was absent in the Adarfl/flMavs/ Ert2-Cre-
expressing mice, demonstrating that MAVS controls the entireIinflammatory response caused by Adar deletion in adult mice
(Figure 7C). However, we found that the small intestines of
mice with Adar deletion on a Mavs/ background were short-
ened relative to Cre-expressing control mice, and their colons
were thickened and devoid of formed stools (Figure 7D). Histo-
logical analysis revealed a disruption of intestinal homeostasis
in these mice (Figures 7E and 7F), reminiscent of the intestinal
phenotype of Adar/Mavs/ and Adar p150/Mavs/
mice. Together, these data demonstrate that the requirement
for ADAR1 in regulation of both the MDA5-MAVS pathway and
tissue homeostasis is maintained in adult mice.mmunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc. 939
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Figure 7. ADAR1 Regulates Both the MDA5-MAVS Pathway and Tissue Homeostasis in Adults
Mice were treated with 2 mg tamoxifen i.p. daily for 3 days and observed for gross pathology.
(A) Samples of the ear were genotyped for Adar deletion after tamoxifen treatment.
(B) Surface body temperate readings for tamoxifen-treated mice at 20–120 hr after initial tamoxifen injection.
(C) Serum cytokine levels determined from mice at day 3 or day 8.
(D) Ex vivo dissection of the gastrointestinal tract at day 8; stomach (S), small intestine (SI), cecum (Ce), and large intestine (LI) are indicated.
(E) Representative hematoxylin and eosin-stained ileum sections of tamoxifen-treated mice of the indicated genotypes at day 8. Original magnification is indi-
cated in the bottom right.
(F) Histological scoring of inflammation in the gut at day 8. Abbreviations are as follows: SI, small intestine; CE, cecum; Prox, proximal colon; Mid, mid-colon.
Mean inflammation score of Adarfl/flMavs/ UBC:Ert2Cre+ intestines compared to either control is significant by one-way ANOVA, p = 0.002.DISCUSSION
Our findings reveal two important roles for ADAR1. First, ADAR1
is a specific and essential negative regulator of the MDA5- and
MAVS-dependent antiviral response. Second, ADAR1 is a key
regulator of multi-organ development and homeostasis, inde-
pendent of the MDA5-MAVS pathway. These roles are both
genetically and temporally separable, with the MDA5-MAVS
pathway entirely responsible for the embryonic lethality, and
the MDA5-MAVS-independent pathway responsible for the
postnatal mortality of Adar/ mice. Moreover, we demonstrate
that ADAR1 isoforms independently contribute to these two940 Immunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc.functions, with the p150 isoform essential for regulation of the
MDA5-MAVS pathway and the p110 isoform contributing to
development. Finally, we demonstrate that ADAR1 regulates
both innate immunity and tissue homeostasis in adult mice.
Our data provide insight into the ADAR mutations in humans
that cause AGS (Crow et al., 2015; Rice et al., 2012). The regula-
tion of the MDA5-MAVS pathway by ADAR1 p150, and not the
RIG-I-MAVS pathway, strongly suggests that ADAR1 p150mod-
ifies a discrete pool of RNAs to prevent their specific detection by
MDA5. Moreover, our findings reveal a clear genetic pathway
linking the ADAR and IFIH1 mutations found in AGS (Rice
et al., 2012, 2014), a rationale for the ADAR AGS mutations
that affect only the p150 isoform of ADAR1 (Crow et al., 2015;
Rice et al., 2012), and a biological framework for understanding
the numerous IFIH1 polymorphisms in humans that are associ-
ated with type I diabetes, systemic lupus erythematosus, and
Graves disease (Gateva et al., 2009; Nejentsev et al., 2009;
Smyth et al., 2006; Sutherland et al., 2007). Given the embryonic
lethality and robust IFN signature of Adar/mice, as well as the
rapid MAVS-dependent inflammatory response that arises after
abruptAdar deletion in adults, we propose that the ADAR1-regu-
lated endogenous MDA5 RNA ligands are broadly expressed,
highly immunostimulatory, or both. Definitive identification of
these RNAs will provide insight into the elusive ligand specificity
of MDA5 (Wu et al., 2013), with implications for the underlying
mechanisms of self/non-self discrimination by intracellular nu-
cleic acid sensors.
Analysis of Adar/ and Adar p150/ mice on a Mavs/
background revealed isoform-specific contributions of ADAR1
to kidney development, intestinal homeostasis, B cell develop-
ment, and 5-HT2C serotonin receptor editing. Further work will
be required to determine whether these functions are mediated
by ‘‘precision editing’’ of adenosines in mRNA open reading
frames that result in new coding potential (as is the case for
5-HT2C), or whether some of these functions require previously
described roles for ADAR1 in control of micro-RNA processing,
mRNA stability, or mRNA 30 UTR length (Ota et al., 2013; Bahn
et al., 2015).
Importantly, no AGS patients are homozygous for null alleles
of ADAR, andmost AGSmutant ADAR1 enzymes are competent
for RNA editing in vitro (Rice et al., 2012). Distinct ADAR muta-
tions in humans also cause dyschromatosis symmetrica hered-
itaria ([DSH] OMIM: 127400) (Hayashi and Suzuki, 2013) and
bilateral striatal necrosis ([BSN] OMIM: 271930) (Livingston
et al., 2014). Some DSH and BSN cases are associated with a
mild IFN signature that is less pronounced compared to AGS
with ADAR mutations, but the clinical presentations of DSH
and BSN differ significantly from classical AGS (Livingston
et al., 2014; Rice et al., 2012). Our identification of an MDA5-
MAVS-independent role for ADAR1 in development and tissue
homeostasis might shed light on the various human phenotypes
associated with ADAR mutations. We propose that the more
than 150 known mutations in ADAR represent a spectrum of ef-
fects on ADAR1 regulation of the MDA5-MAVS pathway versus
ADAR1 control of tissue homeostasis. Specific disease presen-
tations might reflect the extent to which each pathway is
compromised by a particular mutation. For example, AGS muta-
tions probably impact primarily the MDA5-MAVS response
controlled by the p150 isoform, leaving the developmental roles
of ADAR intact.
A very recent study by Walkley and colleagues described the
phenotype of knockin mice with a point mutation in the Adar
gene that disrupts catalytic activity (E861A) (Liddicoat et al.,
2015). Consistent with our findings, they identified two individual
AdarE861A/E861AIfih1/mice that were rescued to birth. Interest-
ingly, and in contrast to our data demonstrating fully pene-
trant postnatal mortality in Adar/Ifih1/ mice, the rescued
AdarE861A/E861AIfih1/ mice were largely normal in appearance,
with no evident gross lesions. It is tempting to speculate that the
differences in postnatal phenotypes revealed in our study and
theirsmight reflect an important distinction between the catalyticImutant and the null allele of Adar. A direct comparison of the null
allele and the catalytic mutant allele of Adar on an Ifih1/ or
Mavs/ background would resolve this issue.
In summary, we have identified independent roles for ADAR1
isoforms in regulation of the antiviral response and control of tis-
sue development and homeostasis, with implications for the hu-
man diseases caused by ADAR mutations.
EXPERIMENTAL PROCEDURES
Mice
Adarfl/fl mice were kindly provided by Dr. Stuart Orkin (Hartner et al.,
2009) and were bred to B6.129S4-Meox2tm1(cre)Sor mice (RRID: IMSR_
JAX:003755) to delete the Adar allele in the germline and to B6;129S-
Tg(UBC-cre/ERT2)1Ejb mice (RRID: IMSR_JAX:008085) to allow for tamox-
ifen-induced widespread deletion of Adar in adult mice. Both Cre-expressing
mouse lines were purchased from the Jackson Laboratory (stock numbers
003755 and 008085). The Adar+/ mice resulting from the B6.129S4-
Meox2tm1(cre)Sor cross were subsequently bred to Tmem173/ (Sting/)
mice (Ishikawa et al., 2009), Mavs/ mice (Gall et al., 2012), Ddx58/
(Rigi/) mice (Kato et al., 2005), or Ifih1/ (Mda5/) mice (Gitlin et al.,
2006). Adar p150+/ gametes were generously provided by Dr. M.B.A. Old-
stone (Ward et al., 2011). Sentinel mice (Crl:CD1[ICR]; Charles River) were
tested quarterly for endo- and ectoparasites, mouse hepatitis virus, mouse
parvovirus, and rotavirus and tested annually for Mycoplasma pulmonis,
pneumonia virus of mice, reovirus 3, Sendai virus, and Theiler murine
encephalomyelitis virus. All experiments were done in accordance with the
Institutional Animal Care and Use Committee guidelines of the University of
Washington.
Histology
Tissues were fixed in 10% neutral buffered formalin, paraffin embedded,
cut into 4- to 5-mm sections, and routinely stained with hematoxylin and
eosin. All tissues were coded to remove genotype identification. Tissues
evaluated included lung, heart, esophagus, kidney, ureter, bladder, liver,
pancreas, spleen, lymph nodes, salivary glands, stomach, small intestine,
large intestine, and reproductive tract. Additionally, for the Adar/Mavs/
mice, decalcified cross sectional images of the skull and brain were also
evaluated.
Flow Cytometry and Cytokine Measurements
Single-cell suspensions from spleen, bonemarrow, thymus, or bloodwere iso-
lated and stained with antibodies for CD3 (145-2C11), CD4 (RM4-5), CD8b
(H35-17.2), B220 (RA3-6B2), CD11c (N418), CD11b (M1/70), CD45.2 (104),
and/or Ter119; Cells were analyzed with a FACSCanto (BD Biosciences) and
analyzed with FlowJo software (TreeStar; RRID: nif-0000-30575). Measure-
ment of serum cytokines was performed with the Milliplex-70K-PX32 mouse
cytokine/chemokine magnetic bead panel (Millipore), according to the manu-
facturer’s instructions.
Immunofluorescence Microscopy
Spleens were frozen in Optimal Cutting Temperature (OCT) media (Sakura).
Tissues were cut into 7-mm sections and treated with ice-cold acetone.
Sections were stained with directly conjugated antibodies: CD8a (53-6.7,
eBioscience), CD4 (RM4-5, eBioscience), and B220 (RA3-6B2, eBioscience).
Nuclei were stained with 1 mg/ml DAPI. Stained slides were mounted with Pro-
long Gold antifade reagent (Life Technologies), imaged with a Nikon Eclipse
90i microscope, and analyzed with Adobe Photoshop software.
Quantitative RT-PCR
Embryos were harvested into TRIzol (Life Technologies) and homogenized
through an 18-G needle attached to a 3ml syringe, followed by RNA extraction
according to manufacturer’s instructions. RNA was treated with DNase (Am-
bion) and 1 mg was reverse-transcribed using RNA to cDNA EcoDry Premix
(Double Primed) (Clontech). cDNA was used for PCR with EVA Green reagents
(Bio-Rad Laboratories) on a Bio-Rad CFX96 Real-Time System. The abun-
dance of each interferon-stimulated gene mRNA was normalized to that ofmmunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc. 941
HPRT mRNA and results were compared with genetic control embryos for
calculation of relative induction.
The primers used were as follows: Cxcl10 Fwd, 50-AAGTGCTGCCGTCA
TTTTCTGCCTC-30, Cxcl10 Rev, 50-CTTGATGGTCTTAGATTCCGGATTC-30;
Isg15 Fwd, 50-GGTGTCCGTGACTAACTCCAT-30, Isg15 Rev, 50-TGGAAAG
GGTAAGACCGTCCT-30; Ifit1 Fwd, 50-GCCATTCAACTGTCTCCTG-30, Ifit1
Rev, 50-GCTCTGTCTGTGTCATATACC-30; Ifit2 Fwd, 50-AGTACAACGAGT
AAGGAGTCACT-30, Ifit2 Rev, 50-AGGCCAGTATGTTGCACATGG-30 (Primer
bank ID: 6680363a1); Mx1 Fwd, 50-GACCATAGGGGTCTTGACCAA-30, Mx1
Rev, 50-AGACTTGCTCTTTCTGAAAAGCC-30 (Primer bank ID: 6996930a1);
Rsad2 Fwd, 50-TGCTGGCTGAGAATAGCATTAGG-30, Rsad2 Rev, 50-GCTG
AGTGCTGTTCCCATCT-30 (Primer bank ID: 31543946a1); Hprt Fwd, 50-GTT
GGATACAGGCCAGACTTTGTTG-30, Hprt Rev, 50-GAGGGTAGGCTGGCC
TATAGGCT-30 (Spandidos et al., 2010); Htr2c (5ht2c) Fwd, 50-TGTCCCTAGC
CATTGCTGATATG-30, Htr2c Rev, 50-TGTCAACGGGATGAAGAATGCC-30.
Deletion of ADAR1 in Adult Mice
Tamoxifen-induced deletion was performed according to the protocol avail-
able from the Jackson Laboratory. In brief, tamoxifen (Sigma-Aldrich) was dis-
solved in corn oil (Sigma-Aldrich) at 20 mg/ml overnight at 37C, filtered
through a 0.22 mm Millex GP PES membrane, and stored at 4C. Mice were
administered 100 ml of tamoxifen via i.p. injection once a day for 3 days. On
day 4, Adarfl/flMavs+/+ Cre-positive mice were moribund, so no further injec-
tions were given. Mice were sacrificed and analyzed by histology and flow
cytometry.
RNA-Seq Library Preparation
Total RNA was harvest from embryos as described above. Ribosomal RNA
was depleted with the RiboZero Magnetic Kit (Human/Mouse/Rat) from Illu-
mina. Libraries were prepared from the Ribo-depleted RNA using the NEBNext
Ultra RNA Library Prep Kit for Illumina (New England BioLabs) with the
following modifications: Ribo-depleted RNA was fragmented for 5 min at
94C to obtain >300 bp fragments and first strand synthesis reaction was incu-
bated for 50 min at 42C. PCR Library enrichment was performed with the
KAPA HiFi DNA Polymerase (KAPA Biosystems) with Illumina barcoded
sequencing primers. Library size distribution was confirmed on an Agilent
2100 Bioanalyzer with a High Sensitivity DNAChip (Agilent Technologies). Bar-
coded libraries were combined and sequenced with an Illumina NextSeq, re-
sulting in approximately 60million paired-end 150-base pair sequencing reads
per embryo.
Alignment and Analysis of RNA-Seq Data
Fastq files were aligned with STAR 2.4.2a (Dobin et al., 2013), with the
following parameters for the indices: STAR–runMode genomeGenerate–
genomeDir /mnt/indices/–genomeFastaFiles /mnt/genome/Mus_musculus.
GRCm38.dna.SORTED.fa–sjdbGTFfile /mnt/transcriptome/Mus_musculus.
GRCm38.81.gtf–runThreadN 32.
Alignment was performed with the following parameters: STAR–genomeDir /
mnt/indices/–readFilesIn /mnt2/data/run2/${i}_R1.fastq.gz /mnt2/data/run2/
${i}_R2.fastq.gz–readFilesCommand zcat–runThreadN 32–outSAMtype BAM
SortedByCoordinate–quantMode GeneCounts–outFilterMismatchNmax 30–
outFileNamePrefix /mnt/results/run2/${i}.star.–outFilterMultimapNmax 20–
outSAMattributes All.
All alignments were performed on Amazon EC2 c3.8xlarge instance using a
Ubuntu13.04 base AMI. The read count files produced by STAR (unstranded)
were used for differential expression analysis using the Bioconductor package
edgeR (Robinson et al., 2010). After calculation of the normalization factors,
low-expressing genes were discarded. Counts were then subject to the esti-
mateGLMCommonDisp function followed by glmFit. Differential expression
for comparison between phenotypes was then performed with the glmLRT
function. ISGs were annotated with the Interferome web tool (http://www.
interferome.org/interferome/search/showSearch.jspx), defined as all type I
IFN-regulated genes in all tissues of Mus musculus with a cutoff of 3-fold
expression. Read count and fastq files are available at SRA. For bioinformatics
analysis, we used FunRich software to determine the enrichment of specific
biological pathways and transcription factor networks among genes with dys-
regulated expression in both Adar/ and Adar/Mavs/ embryos, relative
to the representation of these pathways in the genome.942 Immunity 43, 933–944, November 17, 2015 ª2015 Elsevier Inc.CRISPR Targeting of ADAR1 in Human Cells
For targeting of ADAR with CRISPR-Cas9, we used a lentiviral vector in which
an RNA polymerase III promoter-driven guide RNA and an RNA polymerase II
promoter-driven Cas9-T2A cassette (including sequence encoding a protein
for resistance to puromycin) were constitutively expressed from a single,
self-inactivating lentivirus upon integration into the host cell genome. Lenti-
virus pseudotyped with vesicular stomatitis virus envelope glycoprotein was
produced by transfection of 2.53 106 HEK293T cells for 48 hr in 10-cm plates
with 10 mg of the CRISPR-Cas9 ADAR targeting construct, 9 mg psPAX-2
(a lentiviral packaging plasmid), and 1 mg pVSV-G (plasmid encoding vesicular
stomatitis virus envelope glycoprotein). 2.5 3 106 HEK293T cells were trans-
duced with the viral supernatants on day 3 after harvest, then were selected
for 3 days with 5 mg/ml puromycin (Life Technologies). Subsequent single-
cell cloning was performed by serial dilution. Targeting of the ADAR locus
via CRISPR was evaluated by restriction fragment length polymorphism with
an ApoI (New England Biolabs) restriction site that overlapped the CRISPR
targeting site. Products were separated by electrophoresis through a 3%
MetaPhor agarose gel (Lonza). ADARmutations were identified by PCR ampli-
fication of the surrounding sequence, cloning into pCDNA3, and sequencing of
nine independent plasmids. ADAR1 protein loss was confirmed by immuno-
blot analysis of whole-cell extracts with or without 24 hr of human IFN-b treat-
ment (100 U/ml, R&D Systems) with rabbit polyclonal anti-ADAR1 (12317; Cell
Signaling Technologies) and mouse monoclonal anti-b actin (AC-74; Sigma).
The sequences of the guide RNA target sequence is (sense) 50-GGACAGGA
GACGGAATTCGC-30.
ISRE-Luciferase Reporter Assays
1 3 105 HEK293T cells with or without ADAR1 expression in 24-well plates
were transfected with 25 ng ISRE-luciferase reporter plasmid (Takara Bio)
with 0, 12.5, 25, 50, 100, or 200 ng of pCDNA.3-expressing human RLRs using
Lipofectamine 2000 (Life Technologies) and then incubated for 24 hr. Cells
were lysed in Passive Lysis Buffer (Promega) and luciferase activity was
assessed via the Luciferase Reporter Assay System (Promega) according to
the manufacturer’s instructions and read with a Centro LB 960 Luminometer
(Berthold Technologies).
Statistical Analysis
Statistical significance of difference between groups was assessed with Wil-
coxon Rank Sum, chi square goodness-of-fit, or two-way ANOVAwith Tukey’s
multiple comparison test, as indicated in the figure legends. Values of p < 0.05
were considered statistically significant. All analyses were performed with
Graph Pad Prism 6 (GraphPad, RRID: rid_000081).
ACCESSION NUMBERS
Read count and fastq files are available at SRA: SRA310234.
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